In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Anti-Falsification Directive: Europe’s Answer to Global Supply Chain Threats

This article was originally published in The Gold Sheet

Executive Summary

The European Union July 1 published its directive on falsified medicines, setting into motion a tightening of Europe’s pharmaceutical supply chain that will for the most part take place over the next 18 months – and that could cost pharmaceutical companies billions of Euros.

Related Content

EU to Soon Require New Barcodes and Anti-Tampering Devices Under FMD
Europe in Brief
U.S. and EU Regulators and Industry Grappling with Track-and-trace Standards to Combat Drug Counterfeiting
With July 2013 Deadline Looming, Debate Continues Over How to Require GMPs for APIs in Europe
Pharma Raises Concerns About Draft EU GDP Guideline
News in Brief
Mutual Reliance Blossoming Among U.S. FDA, EMA, Other Inspectorates
U.S. Legislative Response to Heparin Crisis Begins to Take Shape
Industry is Developing a More Profound Understanding of Excipients
Industry is Developing a More Profound Understanding of Excipients



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts